QualityStocks would like to highlight Transgenomic, Inc.(OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The company has three complementary business divisions: Transgenomic Pharmacogenomic Services is a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development, Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, neurology, mitochondrial disorders, and oncology, and Transgenomic Diagnostic Tools which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics.
In the company’s news yesterday,
Transgenomic announced it was awarded a patent license entitled “Method of Determining the Sensitivity of Cancer Cells to EGFR Inhibitors including Cetuximab, Panitumumab and Erlotinib,” which includes all tumor types and targeted therapies that may be influenced by the gene PIK3CA’s mutation status.
The patent was exclusively licensed by the Montefiore Medical Center, whose inventors, Drs. Sanjay Goel and John Mariadason, demonstrated that key mutations in PIK3CA serve as predictors for the efficacy of EGFR-targeted therapies.
Transgenomic has developed assays for complete detection of PIK3CA mutations using the company’s proprietary SURVEYOR® Scan, REVEAL® ICE COLD-PCR and BLOCker™-Sequencing solutions.
Craig Tuttle, CEO of Transgenomic, said that the number of genes associated with the effectiveness of targeted cancer treatments is increasing. In response, Transgenomic’s aim is to develop a complete portfolio of “best-in-class kits for clinically relevant mutations” by leveraging the company’s proprietary technologies.
“The recent issuing of this important patent is a significant milestone in the continued development of our genetic biomarker intellectual property portfolio,” Tuttle stated in the press release. “Since exclusively licensing this patent we have been able to effectively apply our high sensitivity mutation detection technologies, such as SURVEYOR Scan, REVEAL ICE COLD-PCR and BLOCker-sequencing, to PIK3CA assays in order to be able to detect genetic variations in very low mutant load samples, such as plasma, serum and circulating tumor cells.”
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
